In conclusion, our findings demonstrate that spliceosomal mutations occur in a mutually exclusive manner in breast cancer and that distinct components of the spliceosome are targeted by somatic mutations in different types of breast cancer (eg SF3B1 and SAP130 were found to be preferentially mutated in ER-positive and ER-negative disease, respectively). Here, SF3B1 is linked to breast cancer.